Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

November 10, 2017: By Jon Swedien


Tear Film Completes $9 Series A Round

Tear Film Innovations announced Nov. 7 it completed a $9 million Series A preferred stock funding round.

The San Diego company’s flagship product, the iLux system, is an investigational device for dry eye and is under US FDA review.

The device enables eye care professionals to provide in-office treatment of blocked meibomian glands through targeted heating and compression of affected eyelids. TFI recently completed a multi-site clinical study to demonstrate the safety and efficacy of the system.

Visionary Ventures Fund and Tigris Ventures led the financing round.

exicure-logoExicure Raises $31.4 Million in Private Financing

Exicure has raised about $31.4 million in private financing, the company announced Nov. 6.

The Skokie, Illinois, company is focused on creating drug treatments using three-dimensional spherical nucleic acid constructs. Exicure is pursuing an ophthalmic target candidate but has not disclosed the indication it is seeking. The ophthalmic target candidate would be delivered to the retina via an eye drop.

Exicure is also pursuing chronic conditions and orphan diseases in dermatology, respiratory and gastric disorders, and solid tumors.

In the initial private placement announced in September, Exicure raised approximately $20.1 million. Exicure raised more than $11.2 million in a subsequent financing, for a total of about $31.4 million.

download (2)Genisphere Completes $7 Million Capital Raise

Genisphere has completed a $7 million capital raise, the Hatfield, Pennsylvania, company announced Nov. 1

Genisphere is advancing its 3DNA nanotechnology platform for targeted drug delivery, and its product pipeline includes GL-249, a proposed preventive treatment for posterior capsule opacification (PCO).

PCO is a vision impairing disease that occurs in some adults and in most children following cataract surgery. PCO arises when myofibroblast cells grow in the capsule surrounding the surgical site and form cloudy scar tissue inside the eye that blocks vision. While PCO is treated readily by laser therapy, the procedure is neither risk free nor available in the developing world, Genisphere said.

Genisphere said the money it raised will be used to advance its 3DNA nanotechnology and to serve other corporate purposes.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023